MET and lung carcinoma: In a gefitinib-sensitive lung cancer cell line HCC827, focal amplification of MET was found to stimulate ErbB3 phosphorylation which in turn activated downstream PI3K/Akt signaling axis compensating the inhibitory effect of gefitinib on EGFR [21].